Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Upender Velaparthi

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cancer Research|May 4, 2005
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptorJoan M Carboni, Adrian V Lee, Darryl L Hadsell, et al.
Science Translational Medicine|October 25, 2023
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunityMichael Wichroski, Joseph Benci, Si-Qi Liu, et al.
Journal of Medicinal Chemistry|September 2, 2005
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activityMark Wittman, Joan Carboni, Ricardo Attar, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology AgentUpender Velaparthi, Chetan Padmakar Darne, Jayakumar Warrier, et al.
Journal of Medicinal Chemistry|September 26, 2009
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical developmentMark D Wittman, Joan M Carboni, Zheng Yang, et al.
Journal of Medicinal Chemistry|October 14, 2025
Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-986408Denise C Grünenfelder, Upender Velaparthi, Jayakumar S Warrier, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer Research|May 4, 2005
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptorJoan M Carboni, Adrian V Lee, Darryl L Hadsell, et al.
Science Translational Medicine|October 25, 2023
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunityMichael Wichroski, Joseph Benci, Si-Qi Liu, et al.
Journal of Medicinal Chemistry|September 2, 2005
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activityMark Wittman, Joan Carboni, Ricardo Attar, et al.
ACS Medicinal Chemistry Letters|February 20, 2020
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology AgentUpender Velaparthi, Chetan Padmakar Darne, Jayakumar Warrier, et al.
Journal of Medicinal Chemistry|September 26, 2009
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical developmentMark D Wittman, Joan M Carboni, Zheng Yang, et al.
Journal of Medicinal Chemistry|October 14, 2025
Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-986408Denise C Grünenfelder, Upender Velaparthi, Jayakumar S Warrier, et al.
Pageof 2